What clinicians say about clinical trials, and why.
How clinicians read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question. Each report is a two-minute summary for you, the analysis behind every finding, and evidence your AI agent can order and query, with every view linked to its source.
Explore the report previews
| Trial | Indication | Total statements | Size | Checked | Preview |
|---|---|---|---|---|---|
| Krascendo 1 NCT06497556 · Hoffmann-La Roche | previously treated KRAS G12C-positive non-small cell lung cancer | 314 Of these, 101 from 39 confirmed clinicians | Deep | Nov 1, 2026 | Preview |
| KEYNOTE-B49 NCT04895358 · Merck Sharp & Dohme LLC | HR+/HER2- locally recurrent inoperable or metastatic breast cancer | 74 Of these, 27 from 9 confirmed clinicians | Focused | Oct 31, 2026 | Preview |
| PERSEE NCT04547504 · University Hospital, Brest | first-line advanced NSCLC with PD-L1 ≥50% | 217 Of these, 155 from 44 confirmed clinicians | Standard | Nov 3, 2026 | Preview |
| FOURLIGHT-1 NCT06105632 · Pfizer | HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy | 94 Of these, 31 from 13 confirmed clinicians | Focused | Nov 1, 2026 | Preview |
| G-HOPE-001 NCT06238843 · Innovent Biologics (Suzhou) Co. Ltd. | CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma | 99 Of these, 38 from 7 confirmed clinicians | Focused | Nov 1, 2026 | Preview |
| AMPLIFY-7P NCT05726864 · Elicio Therapeutics | KRAS/NRAS-mutated solid tumors | 255 Of these, 51 from 10 confirmed clinicians | Standard | Nov 4, 2026 | Preview |
6 of 108 reports
# What Erudio is and how to query it
curl https://www.erudio.com/llms.txt
# Every report, with counts, version and links
curl https://www.erudio.com/catalog.json
# One report as JSON or Markdown
curl https://www.erudio.com/reports/{slug}.json{
"mcpServers": {
"erudio": { "url": "https://mcp.erudio.com/mcp" }
}
}
# then ask your agent:
# search_reports({ "drug": "ifinatamab-deruxtecan" })- 108 published reports
- any listed oncology trial built within 24 hours
- every new edition in your term
- every statement source-linked
Check our work before you buy.
What do clinicians say they still need to see about ILD/pneumonitis risk with ifinatamab deruxtecan to judge its benefit–risk balance in pretreated extensive-stage small cell lung cancer?
- 014 of the 24 cited clinicians discuss tolerability and ILD vigilance; one account argues I-DXd’s risks outweigh benefits, another attributes withdrawal to insufficient evidence.
- 023 of the 24 cited clinicians discuss the need for randomized evidence; accounts debate the trial's regulatory status and conditional paths to future approval
- 0315 of the 24 cited clinicians discuss I-DXd responses, dosing and toxicity, including early PFS/OS dissent, durability concerns and a request for randomized evidence.
- 04One interview presents brain activity as potentially treatment-changing, with a small subgroup explicitly qualified
The whole report is free. Trace any finding to the podcast, video or post it came from.
The executive summary, the analysis of every finding, and the verified statements behind them, each linked to its source.
- Meeting prepSpeaker briefs for an MSL visit
- Readout reactionA one-page brief for the VP
- Congress briefingA pre-congress briefing
- Advisory boardsAn advisory board agenda
- Competitive contextA comparison brief
- Evidence gapsAn evidence-gap list
- Practical barriers to usePractical barriers clinicians describe
- Education needs assessmentQuestions for the education grants team
One trial, read three ways.
Every report has the same three parts, for you, for the colleagues you forward it to, and for your AI agent. Enterprise MCP adds the whole commentary corpus for your organization's agents.
Executive summary
Detailed analysis
Structured evidence
Follow a trial for 3, 6 or 12 months: when the commentary changes a finding you get the new edition and a note of what changed. We automatically check subscribed trials for new commentary every week. Each report shows the date of its last check. See everything a report holds. Every license includes CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers; public previews do not. Shown for transparency and conflict-of-interest review; not for targeting or outreach.
A single report, agent included
Buy the current edition, or follow a trial with 3, 6 or 12 months of updates, with no enterprise contract. Trials without a report are built within 24 hours of your order.
Enterprise MCP, the whole corpus
Your agents search all the clinician podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses. Ask “before our advisory board, what has each of these investigators said in public about the trial's safety data?” and get sourced answers.
What you have today, and what Erudio adds
Most teams already pay for some of these. Erudio fills the gap between them: the clinician's own reasoning about a trial, in public, with the source.
- Your own analyst or Medical Director
- Judgment and context, one trial at a time, as time allows.
- Erudio addsHours of podcasts, video and posts already read and sorted by finding, each statement linked to its passage, so their time goes to judgment.
- HCP profile databases
- Who a clinician is: affiliations, publications, trials.
- Erudio addsWhat they said about a trial, where and when, with their reasoning. Use both.
- Social listening
- Mentions and sentiment, mostly from short posts.
- Erudio addsLong-form podcasts and video as well as X, with clinical views kept apart from reactions.
- Field medical insights
- What your MSLs heard in private conversations.
- Erudio addsWhat clinicians say in public, each statement attributed to its speaker, named where their identity is confirmed, with optional verified speaker identities to check who said what. It complements your field insights and never ingests them.
- Agencies and congress reports
- One question per project, in weeks.
- Erudio addsA report on any listed trial within 24 hours, with every source linked, plus every new edition during your plan. With Enterprise MCP, your agent asks the next question itself.
- General AI chat
- Fast answers with uncertain sources.
- Erudio addsEvery statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps.
| You have | It gives you | Erudio adds |
|---|---|---|
| Your own analyst or Medical Director | Judgment and context, one trial at a time, as time allows. | Hours of podcasts, video and posts already read and sorted by finding, each statement linked to its passage, so their time goes to judgment. |
| HCP profile databases | Who a clinician is: affiliations, publications, trials. | What they said about a trial, where and when, with their reasoning. Use both. |
| Social listening | Mentions and sentiment, mostly from short posts. | Long-form podcasts and video as well as X, with clinical views kept apart from reactions. |
| Field medical insights | What your MSLs heard in private conversations. | What clinicians say in public, each statement attributed to its speaker, named where their identity is confirmed, with optional verified speaker identities to check who said what. It complements your field insights and never ingests them. |
| Agencies and congress reports | One question per project, in weeks. | A report on any listed trial within 24 hours, with every source linked, plus every new edition during your plan. With Enterprise MCP, your agent asks the next question itself. |
| General AI chat | Fast answers with uncertain sources. | Every statement checked against its source passage, speakers named as the source names them, versioned editions and stated gaps. |
Public sources only. Every statement linked. Every edition versioned, with corrections in the open.
- Reports are built by AI and checked by automated review. Every report keeps what clinicians said apart from what the primary evidence establishes, and never turns commentary into an efficacy verdict or a consensus. Methods
- Reports state what they do not cover, on every page
- Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
- Co-founder Audun Utengen has published research with clinicians in BMJ, JAMA Oncology and the European Heart Journal
- Security-only SOC 2 Type II report, available under NDA. Non-promotional: no efficacy verdicts, consensus scores or rankings. Trust center